| 主权项 |
1. Composition comprising at least one agent which directly or indirectly affects an activity and/or a level of:
a) at least one gene selected from the group consisting of the nucleotidic sequences set forth by SEQ ID NO: 1 and SEQ ID NO: 3 and coding for an heparin-glucosamine 3-O-sulfotransferase 2 and 4 respectively, and/or b) at least one transcription product of a gene selected from the group consisting of the nucleotidic sequences set forth by SEQ ID NO: 1 and SEQ ID NO: 3 and coding for an heparin-glucosamine 3-O-sulfotransferase 2 and 4 respectively, and/or c) at least one translation product of said genes, said products being set forth respectively by SEQ ID NO: 2 and 4, and/or d) a fragment or derivative or variant of said gene or said transcription or translation product, and/or e) heparan sulfate, in particular 3-O-sulfated heparan sulfate, notably 3-O-sulfated heparan sulfate disaccharides, f) abnormal phosphorylation of the Tau protein and/or total Tau protein,for its use in the treatment or the prevention of a neurodegenerative disease, advantageously a Tauopathy, in particular Alzheimer's disease, provided that said neurodegenerative disease is different from a prion disease, and provided that when said agent directly or indirectly affects the activity and/or the level:
of heparan sulfate, or of abnormal phosphorylation of the Tau protein and/or total Tau protein,therefore, both activities and/or levels of heparan sulfate and of abnormal phosphorylation of the Tau protein and/or total Tau protein are affected by said agent,or the activity and/or the level of at least one other element chosen among said gene, said transcription product of said genes, said translation product of said genes, or said fragment or derivative or variant of said gene or said transcription or translation product is also affected. |
